CISPLATINE VIATRIS 1 mg/1 ml clinical trials

Safety and Efficacy of Neoadjuvant immunotherapy with Durvalumab (MEDI 4736) in combination with neoadjuvant chemotherapy (Gemcitabin/Cisplatin or Gemcitabin/Carboplatin) in patients with operable, high-risk, localized urothelial carcinoma of the upper urinary tract. iNDUCT - GETUG V08

This study is looking at a new combination of treatments for a type of bladder or kidney cancer which has not spread. It combines a new drug (Durvalumab) with standard chemotherapy to see if it can shrink the cancer before surgery, aiming to remove all cancer cells.